摘要
目的:基于体素的自动分析方法可用于通过FDG-PET脑部扫描来检测典型的阿尔茨海默氏病(AD)的皮层低代谢。我们比较了两种经过临床验证的工具的准确性,以了解它们在随访中识别出那些进展为AD的MCI受试者的能力,以评估分析方法对FDG-PET诊断性能的影响。 方法:在EADC PET数据集中,对131个MCI和老年健康对照进行了SPMGrid和BRASS(Hermes Medical Solutions,瑞典斯德哥尔摩)的测试。通过关联由两个软件工具计算的定量参数(z值和t值),并通过测量异常区域的地形重叠(骰子得分),来测试工具之间的一致性。三个独立的专家读者根据两个地图集盲目分配了诊断。我们以转换为AD痴呆症为黄金标准。 结果:分别使用SPMGrid和BRASS计算的t映射和z映射在大多数个案(128/131)和大多数选定的感兴趣区域(ROI)中显示出良好的相关性(R> .50) )(98/116)。但是,这两种工具的低代谢模式的重叠很差(Dice得分为0.36)。诊断性能相当,BRASS显示出显着更高的灵敏度(.82对0.59),SPMGrid显示出更高的特异性(0.87对0.52)。 结论:尽管在预测MCI受试者转化为AD方面具有相似的诊断性能,但这两种工具显示出显着差异,并且工具提供的图谱显示出有限的重叠。这些结果强调了在临床实践中使用FDG-PET分析方法进行标准化的紧迫性。
关键词: FDG-PET,阿尔茨海默氏病,MCI,自动化分析,统计参数映射,低代谢模式。
Current Alzheimer Research
Title:A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer’s Disease in Subjects with Mild Cognitive Impairment
Volume: 17 Issue: 13
关键词: FDG-PET,阿尔茨海默氏病,MCI,自动化分析,统计参数映射,低代谢模式。
摘要:
Objective: Automated voxel-based analysis methods are used to detect cortical hypometabolism typical of Alzheimer’s Disease (AD) on FDG-PET brain scans. We compared the accuracy of two clinically validated tools for their ability to identify those MCI subjects progressing to AD at followup, to evaluate the impact of the analysis method on FDG-PET diagnostic performance.
Methods: SPMGrid and BRASS (Hermes Medical Solutions, Stockholm, Sweden) were tested on 131 MCI and elderly healthy controls from the EADC PET dataset. The concordance between the tools was tested by correlating the quantitative parameters (z- and t-values), calculated by the two software tools, and by measuring the topographical overlap of the abnormal regions (Dice score). Three independent expert readers blindly assigned a diagnosis based on the two map sets. We used conversion to AD dementia as the gold standard.
Results: The t-map and z-map calculated with SPMGrid and BRASS, respectively, showed a good correlation (R > .50) for the majority of individual cases (128/131) and for the majority of selected regions of interest (ROIs) (98/116). The overlap of the hypometabolic patterns from the two tools was, however, poor (Dice score .36). The diagnostic performance was comparable, with BRASS showing significantly higher sensitivity (.82 versus .59) and SPMGrid showing higher specificity (.87 versus .52).
Conclusion: Despite similar diagnostic performance in predicting conversion to AD in MCI subjects, the two tools showed significant differences, and the maps provided by the tools showed limited overlap. These results underline the urgency for standardization across FDG-PET analysis methods for their use in clinical practice.
Export Options
About this article
Cite this article as:
A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer’s Disease in Subjects with Mild Cognitive Impairment, Current Alzheimer Research 2020; 17 (13) . https://dx.doi.org/10.2174/1567205018666210212162443
DOI https://dx.doi.org/10.2174/1567205018666210212162443 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
S-Nitrosylation and Attenuation of Excessive Calcium Flux by Pentacycloundecane Derivatives
Medicinal Chemistry Phytochemicals and Antioxidants: An Evaluation in Understanding the Human Lifeline
Current Nutrition & Food Science Autonomic Sudomotor Dysfunction in Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Management of Type-1 and Type-2 Diabetes by Insulin Injections in Diabetology Clinics - A Scientific Research Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Sensitivity of Different MRI-Techniques to Assess Gray Matter Atrophy Patterns in Alzheimer’s Disease is Region-Specific
Current Alzheimer Research Acetylcholinesterase Inhibitors as a Starting Point Towards Improved Alzheimers Disease Therapeutics
Current Pharmaceutical Design Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Integration of Internet of Things with Quantum Dots: A State-of-the-art of Medicine
Current Pharmaceutical Design Genomic Linkage Between Alzheimer's Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets GABAA Receptor Subtype Selective Cognition Enhancers
Current Drug Targets - CNS & Neurological Disorders miRNAs in Alzheimer Disease – A Therapeutic Perspective
Current Alzheimer Research Synthesis and In vitro Evaluation of Thiadiazole Derivatives as AChE, Bu- ChE and LOX Inhibitors
Letters in Drug Design & Discovery Preface: Highlights of Recent Progress in Alzheimers Disease Research [ Hot Topics in Alzheimers Disease Research (Guest Editor: Debomoy K. Lahiri)]
Current Drug Targets Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention
CNS & Neurological Disorders - Drug Targets Protective Effect of Aspirin Against Oligomeric Aβ42 Induced Mitochondrial Alterations and Neurotoxicity in Differentiated EC P19 Neuronal Cells
Current Alzheimer Research Evidence Based Psychosocial Practices and Recovery from Schizophrenia
Current Psychiatry Reviews Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Current Neuropharmacology Modulatory Effects of pH, Cu+2 and Sheet Breakers on Aggregation of Amyloid Peptides
Protein & Peptide Letters